• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

    5/26/23 12:48:36 PM ET
    $AEY
    $ALAR
    $ANGN
    $BHG
    Office Equipment/Supplies/Services
    Industrials
    Computer Software: Prepackaged Software
    Technology
    Get the next $AEY alert in real time by email

    Gainers

    • Onfolio Holdings, Inc. (NASDAQ:ONFO) gained 73% to $2.02 after the company announced it completed development of a generative AI search tool.
    • Appreciate Holdings, Inc. (NASDAQ:SFR) rose 60% to $0.3221.
    • Elevation Oncology, Inc. (NASDAQ:ELEV) shares jumped 52.2% to $4.58 after adding over 15% on Thursday.
    • Alarum Technologies Ltd. (NASDAQ:ALAR) rose 31.6% to $2.87.
    • Bright Health Group, Inc. (NYSE:BHG) climbed 32% to $10.66.
    • Verastem, Inc. (NASDAQ:VSTM) gained 30% to $0.5847. Verastem highlighted updated data from Part A of RAMP 201 trial.
    • MediaAlpha, Inc. (NYSE:MAX) gained 27.4% to $9.68 after White Mountains Insurance Group, Ltd. and WM Hinson commenced a tender offer for up to 5 million shares of MediaAlpha stock.
    • Marvell Technology, Inc. (NASDAQ:MRVL) rose 27.1% to $62.85 after the company reported strong first-quarter results and said it expects AI revenue to at least double in 2024.
    • Arcus Biosciences, Inc. (NYSE:RCUS) shares climbed 25.8% to $22.01. Citigroup maintained Arcus Biosciences with a Buy.
    • Telos Corporation (NASDAQ:TLS) gained 18.3% to $3.09.
    • iTeos Therapeutics, Inc. (NASDAQ:ITOS) climbed 17.9% to $16.38.
    • eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) shares surged 17% to $0.6190 as the company reported data updates from Phase 2 expansion cohorts evaluating zotatifin in patients with ER+ metastatic breast cancer at the ASCO 2023 Annual Meeting.
    • PDD Holdings Inc. (NASDAQ:PDD) gained 16.3% to $69.83 after the company reported better-than-expected Q1 financial results.
    • Stryve Foods, Inc. (NASDAQ:SNAX) gained 16.3% to $0.82.
    • ENDRA Life Sciences Inc. (NASDAQ:NDRA) climbed 14.7% to $1.5135.
    • PDS Biotechnology Corporation (NASDAQ:PDSB) rose 13.5% to $7.64. PDS Biotechnology announced promising interim data from the VERSATILE-002 Phase 2 clinical trial.
    • Structure Therapeutics Inc. (NASDAQ:GPCR) gained 13.1% to $32.90. Structure Therapeutics initiated Phase 2a study of oral GLP-1 agonist GSBR-1290 for the treatment of Type 2 diabetes and obesity.
    • Angion Biomedica Corp. (NASDAQ:ANGN) shares climbed 12.6% to $0.9573 after gaining around 4% on Thursday.
    • GigaCloud Technology Inc. (NASDAQ:GCT) gained 12.3% to $6.50.
    • Geron Corporation (NASDAQ:GERN) rose 11.6% to $3.4950. Geron highlighted oral presentation at ASCO 2023 meeting; to show 'meaningful continuous transfusion independence observed in imetelstat-treated lower risk MDS patients in IMerge Phase 3.'
    • The Gap, Inc. (NYSE:GPS) shares rose 11% to $8.23 after the retailer turned in a profitable quarter on an adjusted basis, despite analysts forecasting a significant loss.
    • ADDvantage Technologies Group, Inc. (NASDAQ:AEY) gained 9.2% to $0.6496.
    • Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) gained 7.4% to $1.2804 after dropping 8% on Thursday. Shuttle Pharmaceuticals was recently granted U.S. patent #11654157: Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation.

    Losers

    • DLocal Limited (NASDAQ:DLO) dipped 28% to $9.93.
    • View, Inc. (NASDAQ:VIEW) fell 22.2% to $0.1790.
    • SunCar Technology Group Inc. (NASDAQ:SDA) shares fell 22% to $11.75 amid continued volatility following the recent completion of the company's combination with Goldenbridge Acquisition to become a publicly-traded company.
    • ROC Energy Acquisition Corp. (NASDAQ:ROC) fell 21.4% to $8.30.
    • Tilray Brands, Inc. (NASDAQ:TLRY) fell 20.6% to $1.8750 after the company announced pricing of a registered offering of $150 million of unsecured convertible senior notes.
    • USD Partners LP (NYSE:USDP) dropped 19.3% to $1.0650.
    • SpringBig Holdings, Inc. (NASDAQ:SBIG) fell 17.7% to $0.25 as the company announced the pricing of public offering of 13 million shares of its common stock at an at-the-market price of $0.3037.
    • Heart Test Laboratories, Inc. (NASDAQ:HSCS) dropped 17.6% to $1.03.
    • Virgin Galactic Holdings, Inc. (NYSE:SPCE) dipped 16.8% to $3.3650.
    • PagSeguro Digital Ltd. (NYSE:PAGS) fell 15.5% to $10.23 after the company reported first-quarter financial results.
    • Beamr Imaging Ltd. (NASDAQ:BMR) shares dropped 15.4% to $4.1963. Beamr Imaging shares jumped 125% on Thursday after NVIDIA announced the release of NVENC Video Codec SDK 12.1 showcasing the integration with Beamr CABR.
    • Wearable Devices Ltd. (NASDAQ:WLDS) fell 15.3% to $1.1950. Wearable Devices shares jumped over 222% on Thursday after the company announced its Mudra Band for Apple Watch is available for preorder.
    • Oncolytics Biotech Inc. (NASDAQ:ONCY) dropped 15.2% to $1.8328. Oncolytics Biotech reported randomized Phase 2 Data from BRACELET-1 metastatic breast cancer trial in ASCO Annual Meeting Abstract.
    • SAI.TECH Global Corporation (NASDAQ:SAI) fell 14.7% to $1.39.
    • Canaan Inc. (NASDAQ:CAN) fell 14.5% to $2.2050 after the company reported worse-than-expected first-quarter results.
    • Nano Labs Ltd (NASDAQ:NA) fell 14.4% to $2.03 after climbing over 69% on Thursday.
    • Domo, Inc. (NASDAQ:DOMO) dropped 13.8% to $12.78 after the company issued mixed financial guidance.
    • Electra Battery Materials Corporation (NASDAQ:ELBM) dropped 13.5% to $0.9854.
    • Design Therapeutics, Inc. (NASDAQ:DSGN) dropped 11.3% to $6.16.
    • Ulta Beauty, Inc. (NASDAQ:ULTA) shares fell 11.2% to $430.69 after reporting first-quarter results.
    • Hibbett, Inc. (NASDAQ:HIBB) dropped 9.6% to $39.92 following worse-than-expected first-quarter results.
    • The Beauty Health Company (NASDAQ:SKIN) fell 8% to $8.90. JP Morgan maintained Beauty Health with a Neutral and lowered the price target from $13 to $12.
    • X Financial (NYSE:XYF) fell 6% to $3.3483 after jumping around 15% on Thursday.
    • RH (NYSE:RH) shares declined 4.1% to $244.12 after the company posted upbeat quarterly results, but lowered its FY23 adjusted operating margin guidance.

     

    Now Read This: Top 5 Health Care Stocks That Could Blast Off In May

    Get the next $AEY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEY
    $ALAR
    $ANGN
    $BHG

    CompanyDatePrice TargetRatingAnalyst
    Marvell Technology Inc.
    $MRVL
    4/2/2026Buy
    Erste Group
    Tilray Brands Inc.
    $TLRY
    4/2/2026$10.00Neutral → Buy
    Roth Capital
    PDD Holdings Inc.
    $PDD
    3/27/2026$136.00Neutral → Buy
    Nomura
    Structure Therapeutics Inc.
    $GPCR
    3/26/2026Peer Perform
    Wolfe Research
    RH
    $RH
    3/25/2026$185.00 → $165.00Market Perform
    Telsey Advisory Group
    Design Therapeutics Inc.
    $DSGN
    3/16/2026$15.00Buy
    Jefferies
    Verastem Inc.
    $VSTM
    3/12/2026$19.00Buy
    BTIG Research
    Ulta Beauty Inc.
    $ULTA
    3/9/2026$640.00 → $715.00Outperform
    Telsey Advisory Group
    More analyst ratings

    $AEY
    $ALAR
    $ANGN
    $BHG
    SEC Filings

    View All

    SEC Form EFFECT filed by Oncolytics Biotech Inc.

    EFFECT - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

    4/2/26 12:15:11 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Virgin Galactic Holdings Inc.

    S-8 - Virgin Galactic Holdings, Inc (0001706946) (Filer)

    4/1/26 4:32:06 PM ET
    $SPCE
    Transportation Services
    Consumer Discretionary

    SEC Form 10-Q filed by Tilray Brands Inc.

    10-Q - Tilray Brands, Inc. (0001731348) (Filer)

    4/1/26 4:30:43 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $AEY
    $ALAR
    $ANGN
    $BHG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Wu Lei

    4 - GigaCloud Technology Inc (0001857816) (Issuer)

    4/1/26 8:55:43 PM ET
    $GCT
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 4 filed by Chaya Eri

    4 - RH (0001528849) (Issuer)

    4/1/26 8:00:07 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    SEC Form 4 filed by Hargarten Christina

    4 - RH (0001528849) (Issuer)

    4/1/26 8:00:09 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    $AEY
    $ALAR
    $ANGN
    $BHG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 141,000 restricted stock units to eleven new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee's acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The 141,000 restricted stock units granted to the eleven new employees will vest at a rate of twenty-five percent (25%) on the one-year anniversary of the employee's date of hire, with the remaining shares vesting quarterly over the next three (3)

    4/2/26 4:05:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MediaAlpha Launches the Insurance Industry's First Carrier-Approved Conversational AI Application for Carriers and Consumers

    LOS ANGELES, April 02, 2026 (GLOBE NEWSWIRE) -- MediaAlpha, Inc. (NYSE:MAX), the leading customer acquisition infrastructure for insurance carriers, today announced the launch of the first carrier-approved conversational AI application powered by ChatGPT technology for auto insurance shopping. Built on MediaAlpha's trusted programmatic marketplace, the app modernizes how consumers find and connect with auto insurance carriers, while meeting the compliance, accuracy, and brand standards that carriers require. "Conversational AI is changing how consumers research and shop for insurance, and our industry has a responsibility to get this right," said Steve Yi, MediaAlpha Co-Founder and CEO. "

    4/2/26 9:00:00 AM ET
    $MAX
    Real Estate

    Oncolytics Biotech® Completes Domicile Change to the United States

    SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the completion of the previously announced change in the jurisdiction of incorporation of Oncolytics from the Province of Alberta in Canada to the State of Nevada in the United States (the "Domestication") through a series of transactions in which the Company first continued its existence from the Province of Alberta in Canada to the Province of British Columbia in Canada on March 17, 2026. The Company will retain its office in Calgary, while the San Diego office will become the Company's new head

    4/1/26 9:00:00 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEY
    $ALAR
    $ANGN
    $BHG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 7, 2024 - FDA Roundup: June 7, 2024

    For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

    6/7/24 3:46:22 PM ET
    $GERN
    $SRAX
    $SNAP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary

    FDA Approval for RYTELO issued to GERON CORP

    Submission status for GERON CORP's drug RYTELO (ORIG-1) with active ingredient IMETELSTAT has changed to 'Approval' on 06/06/2024. Application Category: NDA, Application Number: 217779, Application Classification: Type 1 - New Molecular Entity

    6/7/24 12:36:59 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

    Submission status for RHODES PHARMS's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (ORIG-1) with active ingredient AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 01/13/2021. Application Category: ANDA, Application Number: 213111, Application Classification:

    1/18/21 5:24:40 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    $AEY
    $ALAR
    $ANGN
    $BHG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Parsons James T. bought $10,300 worth of shares (10,000 units at $1.03), increasing direct ownership by 31% to 41,849 units (SEC Form 4)

    4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

    3/13/26 8:00:03 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Kelly Jared bought $4,848 worth of shares (5,050 units at $0.96), increasing direct ownership by 5% to 114,050 units (SEC Form 4)

    4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

    3/13/26 8:00:01 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Pisano Wayne bought $25,338 worth of shares (30,000 units at $0.84), increasing direct ownership by 6% to 492,414 units (SEC Form 4)

    4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

    2/13/26 7:00:29 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEY
    $ALAR
    $ANGN
    $BHG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Erste Group initiated coverage on Marvell

    Erste Group initiated coverage of Marvell with a rating of Buy

    4/2/26 9:30:54 AM ET
    $MRVL
    Semiconductors
    Technology

    Tilray upgraded by Roth Capital with a new price target

    Roth Capital upgraded Tilray from Neutral to Buy and set a new price target of $10.00

    4/2/26 7:55:13 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    PDD Holdings upgraded by Nomura with a new price target

    Nomura upgraded PDD Holdings from Neutral to Buy and set a new price target of $136.00

    3/27/26 8:43:00 AM ET
    $PDD
    EDP Services
    Technology

    $AEY
    $ALAR
    $ANGN
    $BHG
    Financials

    Live finance-specific insights

    View All

    Onfolio Holdings Inc. Announces Full Year 2025 Financial Results and Provides Corporate Update

    WILMINGTON, Del., March 31, 2026 (GLOBE NEWSWIRE) -- Onfolio Holdings Inc. (NASDAQ:ONFO, ONFOW)) (OTC:ONFOP) ("Onfolio" or the "Company"), an owner-operator of cash-generative online businesses, announces financial results for the full year ended December 31, 2025. The Company's Annual Report on Form 10-K was filed with the Securities and Exchange Commission on March 31, 2026 and is available on the SEC's website at www.sec.gov. Recent Corporate Highlights Secured a $300 million convertible note financing facility in November 2025; approximately $6 million raised to date.Portfolio operating profit grew from approximately $1.4M annually in 2024 to approximately $1.8 million annually by en

    3/31/26 5:30:00 PM ET
    $ONFO
    EDP Services
    Technology

    dLocal to Report First Quarter 2026 Financial Results

    MONTEVIDEO, Uruguay, March 31, 2026 (GLOBE NEWSWIRE) -- DLocal Limited (NASDAQ:DLO, "dLocal" or the "Company")), a leading financial technology company powering payments across emerging markets, intends to release financial results for its first fiscal quarter ended March 31, 2026 on May 14, 2026 after market close. The Company will host a conference call and video webcast on May 14, 2026 at 6:00 p.m. Eastern Time. Please click here to pre-register for the conference call and obtain your dial in number and passcode. The live conference call can be also accessed via audio webcast at the investor relations section of the Company's website, at https://investor.dlocal.com/. An archive of the

    3/31/26 4:10:02 PM ET
    $DLO
    Real Estate

    Virgin Galactic Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Sales Open for Virgin Galactic Spaceflight Expeditions - Priced At $750K First of Two New SpaceShips Progressing to Ground Test Phase in April; Flight Test Phase Begins Q3 2026 Commercial Spaceflight Operations with First New SpaceShip Continue on Track for Q4 2026 Second New SpaceShip Expected to Enter Service Between Late Q4 2026 and Early Q1 2027 Virgin Galactic Holdings, Inc. (NYSE:SPCE) ("Virgin Galactic" or the "Company") today announced its financial results for the fourth quarter and full year ended December 31, 2025 and provided a business update. CEO Michael Colglazier said, "We completed pivotal milestones during the first quarter of 2026, and with assembly of our

    3/30/26 4:05:00 PM ET
    $SPCE
    Transportation Services
    Consumer Discretionary

    $AEY
    $ALAR
    $ANGN
    $BHG
    Leadership Updates

    Live Leadership Updates

    View All

    RH Announces the Appointment of Veronica Schnitzius as President, Chief Manufacturing & Sourcing Officer

    RH (NYSE:RH) announced today that Veronica Schnitzius is joining the Company as President, Chief Manufacturing & Sourcing Officer. Veronica will lead RH's efforts to build a global manufacturing platform that combines owned and operated, joint-ventured, and outsourced manufacturing for the Company's core furniture business, which represents 80% of RH brand revenues. The strategy will emulate the vertically integrated model of many of the world's largest and most profitable luxury brands that have a high level of control over the manufacturing, quality and capacity of their core business. Mrs. Schnitzius joins RH after a distinguished 24-year career at American Leather, a leading U.S. br

    3/27/26 8:00:00 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    RH Announces the Appointment of David Stanchak as Chief Real Estate and Transformation Officer

    RH (NYSE:RH) today announced that David Stanchak has returned to the Company as Chief Real Estate and Transformation Officer. Mr. Stanchak has resumed his role leading the Company's Global Real Estate Expansion and North American Gallery Transformation, a position he held from May 2015 through May 2021. Mr. Stanchak will also be leading efforts to monetize the Company's significant portfolio of real estate assets in the United States and Europe. RH Chairman and Chief Executive Officer, Gary Friedman commented, "We are thrilled Dave is rejoining Team RH. His leadership expanding our Gallery platform globally, transforming our legacy stores into Design Galleries with integrated Restaurant

    3/26/26 5:49:00 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    Geron Announces Appointment of New Members to its Board of Directors

    FOSTER CITY, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Patricia S. Andrews and Constantine Chinoporos to its Board of Directors. "We are pleased to welcome Constantine and Pat to the Board, as they bring deep operational expertise cultivated over decades of biopharmaceutical industry leadership, particularly with commercial-stage organizations," said Elizabeth O'Farrell, Chair of the Board. "Their invaluable insights will be instrumental as we execute on our strategic priorities and drive commercial growth for RYTE

    3/26/26 8:00:00 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEY
    $ALAR
    $ANGN
    $BHG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Arcus Biosciences Inc.

    SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

    12/17/24 9:52:58 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by GigaCloud Technology Inc

    SC 13D/A - GigaCloud Technology Inc (0001857816) (Subject)

    12/12/24 3:02:53 PM ET
    $GCT
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form SC 13G filed by iTeos Therapeutics Inc.

    SC 13G - iTeos Therapeutics, Inc. (0001808865) (Subject)

    11/21/24 8:27:38 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care